Here's Why Encompass Health (EHC) is a Strong Value Stock

Encompass Health (EHC), an integrated healthcare provider operating 166 inpatient rehabilitation hospitals, is identified as a strong value stock with a Zacks Rank #2 (Buy) and a Value Style Score of B, supported by a forward P/E of 23.66. The company has experienced positive analyst revisions, with seven analysts raising fiscal 2025 earnings estimates by $0.23 to $5.24 per share in the last 60 days, and boasts a historical average earnings surprise of +14%. This strong positioning, coupled with a B-rated VGM Score, suggests EHC as a notable opportunity for investors seeking undervalued healthcare assets, leveraging Zacks' methodology which has historically delivered significant outperformance.

Analysis

Encompass Health (EHC) is presented as a compelling value opportunity within the healthcare services sector, supported by positive fundamental indicators and strong analyst sentiment. The company holds a Zacks Rank #2 (Buy), a 'B' grade for its Value Style Score, and a forward P/E ratio of 23.66. The core of the bullish thesis rests on improving earnings expectations for fiscal 2025, where seven analysts have revised estimates upwards in the last 60 days, pushing the consensus forecast up by $0.23 to $5.24 per share. This forward-looking optimism is substantiated by a consistent history of operational outperformance, as evidenced by an average earnings surprise of +14%. As a provider of integrated care through its 166 inpatient rehabilitation hospitals, EHC is also strategically positioned to capitalize on the industry trend towards coordinated care models, which could provide a durable tailwind.

Key Decisions for Investors

• Given the strong positive momentum in analyst earnings revisions for fiscal 2025, investors with a value or growth-at-a-reasonable-price mandate should consider EHC for inclusion in their portfolios.
• The combination of a 'B' Value Score and a demonstrated ability to consistently beat earnings estimates by an average of 14% suggests the current valuation may not fully reflect the company's improving fundamental outlook.
• Investors should monitor whether future earnings reports continue this trend of significant positive surprises, as sustained outperformance will be a key catalyst for further share price appreciation and validation of the current buy rating.